Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Chronic Kidney Disease | Editorial

Prime time for chronic kidney disease

Authors: David S. Weisman, Sumeska Thavarajah, Bernard G. Jaar

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Chronic kidney disease (CKD) represents a public health burden worldwide and is associated with significant morbidity and mortality. Most patients with CKD are managed by primary care practitioners and this educational series hope to improve knowledge and delivery of care to this high-risk patient population with CKD.
Literature
1.
2.
Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2021.
3.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
4.
5.
6.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRefPubMed
7.
8.
Moyer VA, on behalf of the U.S. Preventative Services Task Force. Screening for chronic kidney disease: U.S. Preventative Services Task Force Recommendation Statement. Ann Intern Med. 2012;157(8):567–70.CrossRefPubMed
9.
10.
11.
Kramer HJ, Jaar BG, Choi MJ, Palevsky PM, Vassalotti JA, Rocco MV, National Kidney Foundation Kidney Disease Outcomes Quality Initiative. An endorsement of the removal of race from GFR estimation equations: a position Statement from the national kidney Foundation kidney Disease Outcomes Quality Initiative. m J Kidney Dis. 2022;A0(6):691–6.CrossRef
12.
Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. AJKD. 2022;79(2):268–88.CrossRefPubMed
13.
14.
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31. PMID: 24892770.CrossRefPubMedPubMedCentral
15.
Banerjee T, Crews DC, Wesson DE, CDC CKD Surveillance Team, et al. Food insecurity, CKD, and subsequent ESRD in US adults. Am J Kidney Dis. 2017;70(1):38–47.CrossRefPubMedPubMedCentral
16.
United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022.
17.
Crews DC, Bello AK, Saadi G. For theWorld kidney day Steering Committee. Burden, Access, and disparities in Kidnet Disease. Kidney Int. 2019;95(2):242–8.CrossRefPubMed
18.
19.
20.
Metadata
Title
Prime time for chronic kidney disease
Authors
David S. Weisman
Sumeska Thavarajah
Bernard G. Jaar
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03340-w

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue

Case Report

Systemic sarcoidosis presenting as a rare combination of interstitial nephritis with necrotizing vasculitis and urinary retention due to prostate involvement: a case report

Case report

Pseudohypercreatininemia after surgery for aortic dissection: a case report

Research

Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series

Research

The association between albumin and mortality in patients with acute kidney injury: a retrospective observational study

Research

Impact of the COVID-19 pandemic on services for patients with chronic kidney disease: findings of a national survey of UK kidney centres

Research

Prevalence and risk factors of antibodies towards HLA Class I and Class II in Malaysian renal transplant candidates
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits